This 138-page report provides a comprehensive look at life for those living with ankylosing spondylitis (AS) and axial spondyloarthritis (axSpA). Using detailed quantitative data, it gives a full picture of the ankylosing spondylitis / axSpA patient experience - from symptoms to treatment to HCP relationships to quality of life - so you can make informed, strategic decisions, identify opportunities, and understand potential challenges.
Spondyloarthritis is a type of arthritis that affects the joints and the areas where ligaments or tendons attach to bone. Axial spondyloarthritis (axSpA) is an umbrella term that refers to types of arthritis that mostly affect the spine. There are 2 types of axSpA: radiographic, also known as ankylosing spondylitis (AS) and non-radiographic. AS / axSpA impacts around 1% of US adults.
This report offers an in-depth look at the AS / axSpa patient experience. This large-scale, patient-reported data leverages vital quantitative insights essential to understanding key touchpoints in the AS / axSpa patient journey, including condition management, HCP engagement, quality of life, treatment experience and satisfaction, and much more.
This report also addresses important questions that stakeholders may not even know to ask while offering valuable insights into must-have patient-reported data points not available anywhere else. Add-on custom data analysis opportunities are also available for an additional cost - please see the report following purchase for more information.
The analyst is a proven leader in understanding the experiences of people living with chronic health conditions. They reach millions of people through their portfolio of 45+ condition-specific online health communities to provide information, connection, and support to patients and caregivers in the U.S.
Spondyloarthritis is a type of arthritis that affects the joints and the areas where ligaments or tendons attach to bone. Axial spondyloarthritis (axSpA) is an umbrella term that refers to types of arthritis that mostly affect the spine. There are 2 types of axSpA: radiographic, also known as ankylosing spondylitis (AS) and non-radiographic. AS / axSpA impacts around 1% of US adults.
This report offers an in-depth look at the AS / axSpa patient experience. This large-scale, patient-reported data leverages vital quantitative insights essential to understanding key touchpoints in the AS / axSpa patient journey, including condition management, HCP engagement, quality of life, treatment experience and satisfaction, and much more.
What makes this report unique?
Very simply: the focus on patients. This syndicated report is one of the few studies that is based on primary research with diagnosed patients, bringing the patient voice to the forefront.Valuable insights. Informed decisions.
This report lifts the curtain on life with AS / axSpa, giving stakeholders an actionable look at the behaviors, attitudes, perceptions, needs, and experiences of people living with the condition. Data can be used to inform strategic decisions, including product communications, competitive assessments, concept development, landscape analyses, patient journey overlays, and forecasting inputs.This report also addresses important questions that stakeholders may not even know to ask while offering valuable insights into must-have patient-reported data points not available anywhere else. Add-on custom data analysis opportunities are also available for an additional cost - please see the report following purchase for more information.
The analyst is a proven leader in understanding the experiences of people living with chronic health conditions. They reach millions of people through their portfolio of 45+ condition-specific online health communities to provide information, connection, and support to patients and caregivers in the U.S.
This report includes a deep-dive into:
- AS / axSpA patient demographics
- Age, gender, ethnicity, marital status, children, employment status, ocation, insurance, and other health conditions
- Impact of AS / axSpA on quality of life
- Time since diagnosis, current severity of AS / axSpA, impact on quality of life, symptoms experienced, and what patients wish others better understood
- Information-seeking behaviors
- Information sources used, plus topics of interest
- HCP engagement
- Primary HCP seen for condition, satisfaction with HCP, and discussion about brands aware of/not used
- AS / axSpA treatment awareness and experiences
- Aided awareness of specific treatments, treatment experience, satisfaction with current treatments, perceived control with current treatment plan, and interest/participation in clinical trials
Key questions answered in this report:
- To what extent do people say AS / axSpA impacts their overall quality of life?
- What do patients wish others understood about AS / axSpA?
- What percentage of patients see a rheumatologist for AS / axSpA treatment?
- What treatments have the highest aided brand awareness among patients?
- What percentage of patients have undergone surgery?
- How many patients feel their AS / axSpA is well-controlled on their current treatment plan?
- What percentage of patients are likely to switch or add new treatments in the next six months?
- What treatments have patients discussed with their HCP?
- What are the top online resources people with AS / axSpA use to find information?
- What kinds of content and information do patients search for?
- What percentage of patients search for information on treatment options?
Methodology
The report consists of:- A 20-minute online quantitative survey, covering demographics, comorbidities, quality of life/impact, HCP interactions, as well as treatment awareness, experiences, and discussions
- Qualitative patient insights from open-ended responses
- Fielded: January 16, 2023 to April 14, 2023
- Convenient sample of 681 respondents diagnosed with AS / axSpA
- Respondents are age 18+, living in the U.S., and are recruited from proprietary online health communities and recruiting partners
Table of Contents
MethodologyRespondent Demographics
Research Highlights
Condition Status and Quality of Life
- Symptoms Experienced
- Impact on Quality of Life
- Qualitative Patient Insights
- Resources Used to Manage Health
- Types of Content/Information Sought
- Primary HCP Seen for AS / axSpA Care
- Aided Brand Awareness of Treatments
- Treatment Usage
- Condition Control on Current Treatment and Clinical Trial Interest
- Treatment Discussions with HCP
Companies Mentioned
Brands and treatments mentioned in this report include:- ARTHROTEC® (misoprostol, diclofenac sodium)
- CELEBREX® (celecoxib)
- Codeine
- INDOCIN® (indomethacin)
- MINOCIN® (minocycline)
- Mobic® (meloxicam)
- Muscle relaxants (such as Valium®, XANAX®, Flexeril®)
- Neuromodulators or anticonvulsants (such as gabapentin, pregabalin)
- OxyContin®, Percocet®, PERCODAN® (oxycodone)
- Ultram® (tramadol)
- Vicodin® or Lortab® (hydrocodone)
- Voltaren® (diclofenac) tablets
- Voltaren® Gel (diclofenac sodium topical)
- Methotrexate (eg, Rheumatrex®)
- Cyclosporine (Sandimmune®, NEORAL®, GENGRAF®)
- Sulfasalazine (Azulfidine®)
- AMJEVITA™ (adalimumab-atto) Hide until launched in US
- AVSOLA® (infliximab-axxq)
- CIMZIA® (certolizumab)
- COSENTYX® (secukinumab)
- CYLTEZO® (adalimumab-adbm) Hide until launched in US
- ENBREL® (etanercept)
- ERELZI™ (etanercept-szzs) Hide until launched in US
- HULIO® (adalimumab-fkjp) Hide until launched in US
- HUMIRA® (adalimumab)
- HYRIMOZ® (adalimumab-adaz) Hide until launched in US
- INFLECTRA® (infliximab-dyyb)
- IXIFITM (infliximab-qbtx) Hide until launched in US
- REMICADE® (infliximab)
- RENFLEXIS® (infliximab-abda)
- RINVOQ® (upadacitinib)
- SIMPONI ARIA® (golimumab for intravenous infusion)
- SIMPONI® (golimumab)
- TALTZ® (ixekizumab)
- XELJANZ®/XELJANZ® XR (tofacitinib citrate)
- Oral corticosteroids/steroids (eg, prednisone)
- IV corticosteroids/steroids (ie, Solu-Medrol®, methylprednisolone)
- Steroid injection
- H.P. Acthar® Gel (repository corticotropin injection)